{"database":"EGA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"study_type":["Other"],"full_dataset_link":["https://ega-archive.org/studies/EGAS00001003252"],"host":["EGA"],"description":["EGA study EGAS00001003252"],"dataset_title":["A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer (D-Beyond)"],"repository":["EGA"],"category":["restricted"],"name_synonyms":["study, malignant neoplasm of breast, primary breast cancer, malignant tumor of the breast, \"breast neoplasm\" EXACT [MTH:120], Prolia, Xgeva, Patient, Clients, \"mammary tumor\" EXACT [CSP2005:2016-0671], mammary neoplasm, breast tumor, mammary cancer, \"mammary neoplasm\" RELATED [], AMG 162, mammary tumor, \"breast tumor\" EXACT [NCI2004_11_17:C2910], Client, \"neoplasm of breast (disorder)\" EXACT [SNOMEDCT_2005_07_31:126926005]."],"description_synonyms":["l(1)G0410, malignant tumor of the breast, beta-cat-arm, Breasts, PhrB photolyase activity, mammary neoplasm, Lactiferous gland, Human Mammary Neoplasms, Tumor, pigmented epithelium, Technic, glandula mammaria, beta-cat, Techniques, Prolia, Immunogold-Silver Techniques, \"neoplasm of breast (disorder)\" EXACT [SNOMEDCT_2005_07_31:126926005], Immunogold-Silver Technique, 3, cancer of the breast, NUP96, Fs(3)Hor, preoperative procedures, epithelium, ARM, Arm, beta-Cat, BC, average, treatment, Mammary Neoplasms, malignant neoplasm of breast, DmelCG2684, Personnel, Tissue, Human Mammary Carcinomas, pigmented retina, optb2, NTef2, Dm Arm, arm, DNA cyclobutane dipyrimidine photolyase activity, SUPPRESSOR OF AUXIN RESISTANCE 3, Upper, Immunogold-Silver Technic, cancer of breast, disease management, Immunolabeling Technique, Therapies, Malignancies, stage, mammary cancer, Breast Malignant Neoplasms, Immunogold Technics, OPTB2, Tumors, mamma, Therapy, PRE, Upper Arms, Carcinoma, OPG, Receptor activator of nuclear factor kappa-B ligand, \"breast neoplasm\" EXACT [MTH:120], deoxyribonucleic cyclobutane dipyrimidine photolyase activity, Immunogold Technique, beta-catenin/Arm, TNF-related activation-induced cytokine, Girl, Fs(3)Sz11, shortened, Immunogold, OPGL, Immunogold Techniques, KU-MEL-1, Osteoclast differentiation factor, Benign, Immunolabeling Technic, retinal pigment, trance, Lobe of mammary gland, Ly109l, Immunolabeling Technics, dipyrimidine photolyase (photosensitive), opgl, NOS, simple tissue, Technics, General, Malignant Neoplasm of Breast, retinal pigment layer, Carcinomas, l(1)G0234, Clinical Investigator, Benign Neoplasms, Researcher, Immunogold Silver Techniques, \"mammary neoplasm\" RELATED [], EG:86E4.6, Treatments, early, Malignant Neoplasms, NS21, phr A photolyase activity, DNA-photoreactivating enzyme, Brachiums, Patient, breast cancer, betacat, t12687 ALR Dm, Horka, Proliferation, Breast Tumors, ALDR1, CG2684, Breast Malignant Tumors, Fs(3)Horka, DmelCG11579, other neoplasm, short, cancer, invasive procedures, Proliferating, mammary region, RANKL, primary breast cancer, Immunogold-Silver, Neoplasms, developmental stage, ODF, Benign Neoplasm, Mammary Cancers, Surgery, study person role, photoreactivating enzyme activity, Malignant, Human, Breast Malignant Tumor, Trance, brachium, Breast Tumor, Girls, odf, \"mammary tumor\" EXACT [CSP2005:2016-0671], Survey, breast tumor, stratum pigmentosa retinae, TRANCE, DmF2, Upper Arm, Technique, Immunogold Silver Technics, lod, Human Mammary, MOS3, deoxyribocyclobutadipyrimidine pyrimidine-lyase activity, Clinical, PRECOCIOUS, Malignancy, Research, Mammary Neoplasm, proliferating, Mammary Carcinoma, Investigators, mammary part of chest, Women Groups., F23A5.3, Clinical Investigators, stubby, Brachium, Cancer of the Breast, Neoplasias, Xgeva, Malignant Tumor of Breast, Clients, Mammary, Mammary Cancer, operative procedures, Breast, l(1)2Bv, mammary tumor, AMG 162, F23A5_3, Cancer, Breast Carcinoma, Human Mammary Neoplasm, ALR, Breast Carcinomas, Malignant Neoplasm, whole blood, Immunogold Technic, sOdf, Women's Group, Investigator, membrane form, Immunohistocytochemistry, intraoperative procedures, soluble form, \"breast tumor\" EXACT [NCI2004_11_17:C2910], Brustdruese, Client, Woman, HEL-S-6, Tumor necrosis factor ligand superfamily member 11, CD254, l(1)arm, Breast Malignant Neoplasm, MODIFIER OF SNC1, Arms, peroperative procedures, Mammary Carcinomas, deoxyribonucleic photolyase activity, Neoplasm, Osteoprotegerin ligand, DD3, Human Mammary Carcinoma, rankl, Survey Personnel, Immunolabeling, Breast Neoplasm, Immunocytochemistry, RPE, photolyase activity, operative therapy, Women's Groups, Lobe of breast, investigator, operations, hRANKL2, Cancers, l(1)G0192, Lds, upper extremity, p. pigmentosa retinae, CG11579, Therapeutic, sodf, Breast Cancer, perioperative procedures, Immunogold-Silver Technics, cd254, Immunolabeling Techniques, Cancer of Breast, Treatment, Researchers, deoxyribonucleate pyrimidine dimer lyase (photosensitive), Neoplasia, breast"],"additional_accession":[]},"is_claimable":false,"name":"A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer (D-Beyond)","description":"This is a prospective, single arm phase IIa trial in which patients with early breast cancer will receive pre-operatively two doses of denosumab 120mg subcutaneously one week apart (maximum 12 days) followed by surgery. Tumor, normal breast tissue and blood samples will be collected at baseline and at surgery. Post-operative treatment will be at the discretion of the investigator.Primary objective: to determine if a short course of RANKL inhibition with denosumab can induce a decrease in tumor proliferation rates as determined by Ki67 immunohistochemistry (IHC) in newly diagnosed, early stage breast cancer in pre-menopausal women.","dates":{"updated":"2020-01-31 08:54:17"},"accession":"EGAS00001003252","cross_references":{"TAXONOMY":["9606"],"EGA":["EGAD00001004391","EGAC00001000748"]}}